Unlock full details of this profile with our free Lite plan!
Sign Up and Get Free AccessBeiGene - About the company
BeiGene is a public company based in Cambridge (United States), founded in 2010 by John V Oyler. It operates as a Developer of targeted and immune-oncology drugs against cancer. BeiGene has raised $172M in funding from Hillhouse. The company has 593 active competitors, including 189 funded and 140 that have exited. Its top competitors include companies like Moderna, Incyte and Vir Biotechnology.
Company Details
Developer of targeted and immune-oncology drugs against cancer. The company's product pipeline includes oral small molecule inhibitors and monoclonal antibodies, such as BGB-3111, an oral inhibitor of Bruton tyrosine kinase, BGB-283, a B-RAF inhibitor; and BGB-290, a poly (ADP-ribose) polymerase inhibitor. Also, has another candidate BGB-108, a potentially differentiated PD-1 monoclonal antibody candidate.
- Website
- beigene.com
- Email ID
- *****@beigene.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2010
Location
Cambridge, United States
Stage
Public
Total Funding
$172M in 6 rounds
Latest Funding Round
Ranked
2nd among 593 active competitors
Annual Revenue
$2.46B as on Dec 31, 2023
Employee Count
1,090 as on Dec 31, 2022
Investment & Acquisitions
Exit Details
Public
Legal entities associated with BeiGene
BeiGene is associated with 4 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Aug 27, 2015 | $2.46B (as on Dec 31, 2023) | - | - | |
Jan 15, 2019 | - | - | - | |
Dec 31, 2009 | - | 10600 (as on Feb 29, 2024) | - | |
Dec 26, 999 | - | 1090 (as on Dec 31, 2022) | - |
Get your free copy of BeiGene's company profile
BeiGene's funding and investors
Filter this listBeiGene has raised a total funding of $172M over 6 rounds. Its first funding round was on May 02, 2011. Its latest funding round was a Post IPO round on Jul 15, 2020 for $2.1B. 1 investor participated in its latest round, which include Rock Springs Capital, T. Rowe Price, Boxer Capital and Fidelity Investments.
BeiGene has 15 institutional investors including Hillhouse, Rock Springs Capital and T. Rowe Price.
Here is the list of recent funding rounds of BeiGene:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Jul 15, 2020 | $2.1B | Post IPO | 1948846 | 7384671 | |
Oct 31, 2019 | $2.8B | Post IPO | 5816616 | 7162378 | |
May 13, 2015 | $97M | Series B | 8061755 | 9447616 |
Access funding benchmarks and valuations. Sign up today!View details of BeiGene's funding rounds and investors
BeiGene's founders and board of directors
Founder? Claim ProfileThe founders of BeiGene is John V Oyler. John V Oyler is the CEO of BeiGene.
View details of BeiGene's Founder profiles and Board Members
BeiGene's employee count trend
BeiGene has 1,090 employees as of Dec 22. The total employee count is 37.0% more than what it was in Dec 21. Here is BeiGene's employee count trend over the years:Uncover BeiGene's growth story! Sign up today!Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
BeiGene's Competitors and alternates
Top competitors of BeiGene include Moderna, Incyte and Vir Biotechnology. Here is the list of Top 10 competitors of BeiGene, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 80/100 | |
2nd | BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 78/100 | |
3rd | Incyte 1991, Wilmington (United States), Public | Developer of small molecules for the treatment of different cancer and skin diseases | - | 71/100 | |
4th | Vir Biotechnology 2017, San Francisco (United States), Public | Developer of therapeutics for the treatment of infectious diseases | $216M | 69/100 | |
5th | Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public | Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | - | 69/100 | |
6th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $806M | 67/100 | ||
7th | Developer of antibodies for treating cancer | - | 67/100 | ||
8th | Cidara Therapeutics 2013, San Diego (United States), Public | Developer of novel anti-infectives for infectious diseases (bacterial and fungal) | $78.4M | 66/100 | |
9th | Serum Institute of India 1966, Pune (India), Funding Raised | Manufacturer of vaccines and immuno-biological drugs for infectious diseases | - | 66/100 | |
10th | Annexon 2011, San Francisco (United States), Public | Developer of antibodies to treat complement-mediated neurodegenerative diseases | $256M | 65/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on BeiGene's competitors? Click here to see the top ones
BeiGene's Investments and acquisitions
Filter this listBeiGene has not made any acquisitions yet. BeiGene has made 6 investments. Here is the list of latest three $investments:
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Jun 28, 2024 | Investments | 2021 | Huangpu, China | |
Aug 11, 2023 | Investments | 2020 | Pittsburgh, United States | |
Nov 02, 2021 | Investments | 2020 | San Diego, United States |
Want to know more about where corporates are investing? Sign up today!See all investments by BeiGene
Reports related to BeiGene
Here is the latest report on BeiGene's sector:
News related to BeiGene
Filter this listMedia has covered BeiGene for a total of 78 events in the last 1 year, 32 of them have been about company updates and 7 about people movement.
•
BeiGene's turnaround: Burning nearly 60 billion in 11 years, may usher in its first profitable year with a blockbuster drugCICC online•Jun 09, 2025•BeiGene
•
•
BeiGene presents groundbreaking results from cancer research novel treatment approaches for blood cancer and solid tumorsBusiness Wire•May 25, 2025•BeiGene
•
•
•
US patent and brands agency invalidates patent patent of Pharmacyclics claimed against BeigeBusiness Wire•May 01, 2025•BeiGene
•
Beengen delivers update to the clinical development program of Ociperlimab (BGB-A1217)Business Wire•Apr 04, 2025•BeiGene
•
Beigene receives positive CHMP position for Tevimbra® as a first line treatment for small cell lung cancer in the extensive stageBusiness Wire•Apr 01, 2025•BeiGene
•
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesKorea Newswire•Mar 07, 2025•BeiGene
•
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancerPharmaceutical Technology•Mar 05, 2025•BeiGene
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about BeiGene
Explore our recently published companies
- Cartwheel - Reno based, 2021 founded, Seed company
- Laconstancia - Unfunded company
- Iconier - Las Vegas based, 2020 founded, Unfunded company
- Springbrook Wellness - Kenosha based, 2011 founded, Public company
- Nisoltus Medical - New Orleans based, 2015 founded, Unfunded company
- Tilit - Helsinki based, 2023 founded, Unfunded company